KAMADA » INVESTORS

INVESTMENT HIGHLIGHTS

  • Rapidly Growing, Globally Positioned Biopharmaceutical Company
    - Focused on Orphan Diseases and Plasma Derived Protein Therapeutics
     
  • Flagship Product Glassia® Approved for Alpha-1 Antitrypsin Deficiency Disorder
    - Has a Unique and Differentiated Product Profile and Represents an Exciting Growth Opportunity
     
  • Significant Opportunity in Novel Inhaled AAT Undergoing Pivotal Clinical Development
     
  • Validating Strategic Partnerships with Industry Leaders Baxter, Chiesi, Kedrion and Pari Pharma
     
  • Valuable R&D Pipeline Focused on Various Orphan Indications
     
  • Integrated, Efficient and Scalable Best-in-class Patented Platform Technology and Know-How
     
  • Strong Financial Profile with Increasing Profitability

LATEST NEWS

Kamada Reports Financial Results for Fourth Quarter and Full-Year 2017

Feb. 7, 2018

Kamada Reports Financial Results for Fourth Quarter and Full-Year 2017.

Kamada Announces Interim Results from Phase 2 Clinical Trial of Intravenous Alpha-1 Antitrypsin Treatment for Prevention of Lung Transplant Rejection

Jan. 8, 2018

The company announced interim results from the Company’s Phase 2 trial of intravenous Alpha-1 Antitrypsin (IV AAT) for the prevention of lung transplant rejection.

More News

FINANCIAL REPORTS

Annual Report 2017

Dec. 31, 2017

Q3 / 2017 Financial Report

Nov. 14, 2017

Q2 / 2017 Financial Report

Jun. 30, 2017

More Reports

STOCK QUOTE

NASDAQ

KMDA:$0
Change:0.00%
Date & Time:
For more information: KAMADA on NASDAQ website

TASE

Share price                                             Daily volume(NIS)                

Click here for more information 

 Convertible bond                                  Daily volume(NIS)

Click here for more information

 For more information: KAMADA on Tel- Aviv Stock Exchange website

CORPORATE GOVERNANCE

Please click "Read more" to view Kamada's Corporate Governance items.

Read more

IR CONTACT & FAQ

Chaime Orlev,
CFO
ir@kamada.com

Bob Yedid
LifeSci Advisors
646-597-6989
bob@lifesciadvisors.com

 

Read more